{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-127154","form_type":"8-K","ticker":null,"cik":"0001633070","company_name":"Axcella Health Inc.","filed_at":"2022-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.506676+00:00","generated_at":"2026-06-21T04:09:44.813245+00:00","sec_items":["2.05","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Axcella cuts 85% workforce, suspends NASH trial, focuses on Long COVID","bullets":["Board approves reduction in force of ~85%, affecting CFO Robert Crane and Chief People Officer Virginia Dean, effective Dec 14.","Records Q4 2022 restructuring charge of up to $2.1M for severance and related costs.","Immediately suspends EMMPACT Phase 2b trial of AXA1125 for NASH to focus on Long COVID Fatigue.","Reaches agreement with SLR Investment Corp. to pay down remaining debt under Loan and Security Agreement.","Initiates strategic alternatives review with investment bank to maximize shareholder value; no assurances of transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-127154","json":"https://secwatch.observer/filing/0001104659-22-127154.json","markdown":"https://secwatch.observer/filing/0001104659-22-127154.md","text":"https://secwatch.observer/filing/0001104659-22-127154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1633070/000110465922127154/0001104659-22-127154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1633070/000110465922127154/tm2232767d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:09:44.813245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e10f897a67","claim":"Robert Crane resigned as Chief Financial Officer at Axcella Health Inc..","evidence_excerpt":"Robert Crane, the Company’s Chief Financial Officer and principal financial officer and Virginia Dean, the Company’s Senior Vice President, Chief People Officer will step down from their positions effective December 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1633070/000110465922127154/0001104659-22-127154-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e5442fc38c","claim":"Virginia Dean resigned as Chief People Officer at Axcella Health Inc..","evidence_excerpt":"Robert Crane, the Company’s Chief Financial Officer and principal financial officer and Virginia Dean, the Company’s Senior Vice President, Chief People Officer will step down from their positions effective December 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1633070/000110465922127154/0001104659-22-127154-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief People Officer"}],"fact_type":"executive_change"},{"claim_id":"d1e8a4a9c711f604ca36df802730752c1e5906f1","claim":"Axcella Health Inc. announced a restructuring with charges of up to $2.1 million (approximately 85% of the Company's workforce).","evidence_excerpt":"As part of this restructuring, the Board approved a reduction in force of approximately 85% of the Company's workforce. Robert Crane, the Company's Chief Financial Officer and Virginia Dean, the Company's Senior Vice President, Chief People Officer were each part of the reduction in force. The reduction in force is a measure to manage costs and conserve cash resources with the goal of maximizing the opportunities available to Axcella during the Board's review of strategic alternatives to maximize shareholder value. The Company expects to record a charge of up to $2.1 million in the fourth quarter of 2022 relating to the reduction in force, which is expected to consist of employee severance and other restructuring related costs and expenses.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1633070/000110465922127154/0001104659-22-127154-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"up to $2.1 million"},{"label":"Headcount","value":"approximately 85% of the Company's workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}